search
Back to results

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) (DANNOAC-VTE)

Primary Purpose

Deep Vein Thrombosis, Pulmonary Embolism

Status
Recruiting
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Dabigatran Etexilate Oral Capsule
Rivaroxaban Oral Tablet
Edoxaban Oral Tablet
Apixaban Oral Tablet
Sponsored by
Herlev and Gentofte Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Deep Vein Thrombosis focused on measuring Non-vitamin K antagonist oral anticoagulation, Non-vitamin K Antagonist Oral Anticoagulants, Direct-acting Oral Anticoagulants, Novel oral anticoagulant drugs

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • A diagnosis of VTE in outpatient clinic or as discharge diagnosis after hospitalization.
  • A claimed prescription of a NOAC from a Danish pharmacy within 14 days of discharge or outpatient clinic visit.

Exclusion Criteria:

  • A prescription of a NOAC within 90 days prior to hospitalization or outpatient clinic visit for VTE.
  • Patients with NOAC preference apart from preference consistent with current cluster randomized NOAC.
  • Other contraindications mentioned in the "Summary of Product Characteristics" for the respective NOAC.

Sites / Locations

  • Aarhus University Hospital
  • Bispebjerg HospitalRecruiting
  • Amager HospitalRecruiting
  • Rigshospitalet
  • Bispebjerg and Frederiksberg HospitalRecruiting
  • Esbjerg HospitalRecruiting
  • Nordsjællands Hospital - FrederiksundRecruiting
  • Herlev Gentofte HospitalRecruiting
  • Glostrup Hospital - Department of Emergency MedicineRecruiting
  • Glostrup Hospital - Department of Medicine / CardiologyRecruiting
  • Glostrup Hospital - Department of NeurologyRecruiting
  • Herlev-Gentofte Hospital - Department of MedicineRecruiting
  • Nordsjællands Hospital - HillerødRecruiting
  • Hjørring Hospital
  • Holbæk HospitalRecruiting
  • Hvidovre HospitalRecruiting
  • Næstved Hospital
  • Odense University Hospital - Department of CardiologyRecruiting
  • Odense University Hospital - Department of Emergency MedicineRecruiting
  • Odense University Hospital - Department of GeriatricsRecruiting
  • Zealand University Hospital - Department of NeurologyRecruiting
  • Zealand University Hospital Roskilde - Department of Cardiology
  • Bornhoms HospitalRecruiting
  • Slagelse Hospital
  • Odense University Hospital SvendborgRecruiting
  • Vejle HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Dabigatran

Rivaroxaban

Edoxaban

Apixaban

Arm Description

After randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.

After randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.

After randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.

After randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.

Outcomes

Primary Outcome Measures

Primary efficacy outcome: a composite endpoint of new venous thromboembolism or all-cause death.
First occurrence of new venous thromboembolism or all-cause death. Information of endpoints and comorbidity is obtained from the Danish National Patient Register based on ICD-10 diagnostic codes and information of vital status and date of death will be obtained from the Central Person Register. Information of prescribed drug will be obtained using information from the Danish Registry of Medicinal Product Statistics.

Secondary Outcome Measures

Secondary efficacy outcome: New venous thromboembolism.
Information of endpoints and comorbidity is obtained from the Danish National Patient Register based on ICD-10 diagnostic codes and information of vital status and date of death will be obtained from the Central Person Register. Information of prescribed drug will be obtained using information from the Danish Registry of Medicinal Product Statistics.
Secondary efficacy outcome: All-cause death.
Information of endpoints and comorbidity is obtained from the Danish National Patient Register based on ICD-10 diagnostic codes and information of vital status and date of death will be obtained from the Central Person Register. Information of prescribed drug will be obtained using information from the Danish Registry of Medicinal Product Statistics.
Primary safety outcome: bleeding requiring hospitalization.
First occurrence of bleeding requiring hospitalization. Information of endpoints and comorbidity is obtained from the Danish National Patient Register based on ICD-10 diagnostic codes and information of vital status and date of death will be obtained from the Central Person Register. Information of prescribed drug will be obtained using information from the Danish Registry of Medicinal Product Statistics.

Full Information

First Posted
April 18, 2017
Last Updated
July 5, 2023
Sponsor
Herlev and Gentofte Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03129555
Brief Title
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
Acronym
DANNOAC-VTE
Official Title
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 1, 2023 (Actual)
Primary Completion Date
March 31, 2027 (Anticipated)
Study Completion Date
March 31, 2029 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Herlev and Gentofte Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in venous thromboembolism across Danish hospitals.
Detailed Description
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists, but such data are warranted to evaluate if the four NOACs are equal in treatment of venous thromboembolism (VTE) without an additional cost of increased bleeding risk. Furthermore, classic randomized trials are highly selective, as elderly and/or fragile patients and patients with comorbidity are underrepresented. Therefore, there is a need of randomized trials that include a broader population of patients. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in VTE across Danish hospitals. The aim of the present study is to: 1) examine if the four NOACs are equally effective in treatment of VTE without increasing the risk of major bleeding requiring hospitalization; 2) conduct a randomized study that includes elderly and fragile patients and patients with comorbidity that would otherwise not be included in a traditional randomized clinical trial. For a variety of reasons, Danish hospitals and clinicians often prefer one particular NOAC. This can make work simpler for the busy clinician, although there may also be economic advantages on a local or a regional larger scale. For a period of two years, this study will replace this individually or hospital preferred selection with a random selection. The hospitals and clinics that participate in this study will be randomly selected to primarily use one specific NOAC for 6 months at a time during a total period of two years. This only applies to patients with VTE that are selected by the physician to be eligible for NOAC treatment. VTE refers to deep vein thrombosis and pulmonary embolism, or a combination of both. Endpoints Primary efficacy outcome: a composite endpoint of new venous thromboembolism or all-cause death. Secondary efficacy outcomes: Individually components of the primary endpoints; new venous thromboembolism or all-cause death. Primary safety outcome: bleeding requiring hospitalization. Other effect measures: discontinuation of therapy. adherence to therapy. other reasons of admission to hospital than included in the primary and secondary endpoint. Sensitivity analyses: primary endpoint stratified by gender. primary endpoint stratified by age (≤65, 65-75, >75 years of age). primary endpoint stratified by levels of the CHA2DS2VASc score (0-1, 2-3, >3). primary endpoint with exclusion of clusters with non-compliance greater than 20% of cluster randomization. primary endpoint where the actual treatment is used instead of the allocated treatment. primary safety endpoint stratified by HAS-BLED score. Information of endpoints and comorbidity is obtained from the Danish National Patient Register based on ICD-10 diagnostic codes and information of vital status and date of death will be obtained from the Central Person Register. Drug discontinuation and adherence will be examined using information from the Danish Registry of Medicinal Product Statistics. The prespecified endpoints will be evaluated after 6 months as intention-to-treat analysis. In addition, the prespecified endpoints will be evaluated after 12 months and 5 years. A cluster is defined as a hospital or a cardiology clinic. The Clusters will be enrolled in the study from 1. of April 2023 to 1. October 2023.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Deep Vein Thrombosis, Pulmonary Embolism
Keywords
Non-vitamin K antagonist oral anticoagulation, Non-vitamin K Antagonist Oral Anticoagulants, Direct-acting Oral Anticoagulants, Novel oral anticoagulant drugs

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Model Description
Cluster randomized cross-over study
Masking
Outcomes Assessor
Masking Description
The Outcome Assessor will only have a code of each drug and a code for each cluster. Therefore he will not know what drug the clusters have been using. The randomization key will be safely stored at servers at "Statens Serums Institute" (An institute under the Danish Ministry of Health). After the primary and secondary outcome have been evaluated data will be unblinded.
Allocation
Randomized
Enrollment
5000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Dabigatran
Arm Type
Active Comparator
Arm Description
After randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
Arm Title
Rivaroxaban
Arm Type
Active Comparator
Arm Description
After randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
Arm Title
Edoxaban
Arm Type
Active Comparator
Arm Description
After randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
Arm Title
Apixaban
Arm Type
Active Comparator
Arm Description
After randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
Intervention Type
Drug
Intervention Name(s)
Dabigatran Etexilate Oral Capsule
Intervention Description
After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Intervention Type
Drug
Intervention Name(s)
Rivaroxaban Oral Tablet
Intervention Description
After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Intervention Type
Drug
Intervention Name(s)
Edoxaban Oral Tablet
Intervention Description
After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Intervention Type
Drug
Intervention Name(s)
Apixaban Oral Tablet
Intervention Description
After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Primary Outcome Measure Information:
Title
Primary efficacy outcome: a composite endpoint of new venous thromboembolism or all-cause death.
Description
First occurrence of new venous thromboembolism or all-cause death. Information of endpoints and comorbidity is obtained from the Danish National Patient Register based on ICD-10 diagnostic codes and information of vital status and date of death will be obtained from the Central Person Register. Information of prescribed drug will be obtained using information from the Danish Registry of Medicinal Product Statistics.
Time Frame
6 months.
Secondary Outcome Measure Information:
Title
Secondary efficacy outcome: New venous thromboembolism.
Description
Information of endpoints and comorbidity is obtained from the Danish National Patient Register based on ICD-10 diagnostic codes and information of vital status and date of death will be obtained from the Central Person Register. Information of prescribed drug will be obtained using information from the Danish Registry of Medicinal Product Statistics.
Time Frame
6 months.
Title
Secondary efficacy outcome: All-cause death.
Description
Information of endpoints and comorbidity is obtained from the Danish National Patient Register based on ICD-10 diagnostic codes and information of vital status and date of death will be obtained from the Central Person Register. Information of prescribed drug will be obtained using information from the Danish Registry of Medicinal Product Statistics.
Time Frame
6 months.
Title
Primary safety outcome: bleeding requiring hospitalization.
Description
First occurrence of bleeding requiring hospitalization. Information of endpoints and comorbidity is obtained from the Danish National Patient Register based on ICD-10 diagnostic codes and information of vital status and date of death will be obtained from the Central Person Register. Information of prescribed drug will be obtained using information from the Danish Registry of Medicinal Product Statistics.
Time Frame
6 months.
Other Pre-specified Outcome Measures:
Title
Discontinuation of therapy.
Description
Drug discontinuation will be examined using information from the Danish Registry of Medicinal Product Statistics.
Time Frame
6 months.
Title
Adherence to therapy.
Description
Drug adherence will be examined using information from the Danish Registry of Medicinal Product Statistics.
Time Frame
6 months.

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A diagnosis of VTE in outpatient clinic or as discharge diagnosis after hospitalization. A claimed prescription of a NOAC from a Danish pharmacy within 14 days of discharge or outpatient clinic visit. Exclusion Criteria: A prescription of a NOAC within 90 days prior to hospitalization or outpatient clinic visit for VTE. Patients with NOAC preference apart from preference consistent with current cluster randomized NOAC. Other contraindications mentioned in the "Summary of Product Characteristics" for the respective NOAC.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gunnar H Gislason, MD, PhD
Phone
29341524
Email
Gunnar.Gislason@regionh.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Casper N Bang, MD, PhD
Email
casper.niels.furbo.bang@regionh.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gunnar H Gislason, MD, PhD
Organizational Affiliation
Herlev Gentofte Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Aarhus University Hospital
City
Aarhus
ZIP/Postal Code
8200
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erik Grove, MD
Email
erikgrove@dadlnet.dk
First Name & Middle Initial & Last Name & Degree
Erik L Grove, MD
Facility Name
Bispebjerg Hospital
City
Copenhagen NV
ZIP/Postal Code
2400
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Birgitte U Nygaard, MD
Phone
38 63 50 00
Facility Name
Amager Hospital
City
Copenhagen S
ZIP/Postal Code
2300
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jens Brønnum-Schou, MD
Phone
+45 32 34 32 34
Email
jens.Broennum-Schou@regionh.dk
Facility Name
Rigshospitalet
City
Copenhagen Ø
ZIP/Postal Code
2100
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lars Køber, MD
Phone
+45 35 45 35 45
Email
Lars.Koeber@regionh.dk
Facility Name
Bispebjerg and Frederiksberg Hospital
City
Copenhagen
ZIP/Postal Code
2400
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Hermann, MD, PhD
Email
thomas.steffen.hermann@regionh.dk
Facility Name
Esbjerg Hospital
City
Esbjerg
ZIP/Postal Code
6700
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Majed Husain, MD
Email
Majed.H.husain@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Majed Husain, MD
Facility Name
Nordsjællands Hospital - Frederiksund
City
Frederikssund
ZIP/Postal Code
3600
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Louise Schierbeck, MD
Phone
+45 48 29 50 00
Email
louise.schierbeck.01@regionh.dk
Facility Name
Herlev Gentofte Hospital
City
Gentofte
ZIP/Postal Code
2900
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gunnar Gislason, MD
Phone
+45 38 67 38 67
Email
Gunnar.Gislason@regionh.dk
First Name & Middle Initial & Last Name & Degree
Jonas Olesen, MD
Facility Name
Glostrup Hospital - Department of Emergency Medicine
City
Glostrup
ZIP/Postal Code
2600
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ekim Seven, MD
Email
ekim.seven@regionh.dk
Facility Name
Glostrup Hospital - Department of Medicine / Cardiology
City
Glostrup
ZIP/Postal Code
2600
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jesper P Hansen, MD
Email
jesper.park.hansen.01@regionh.dk
Facility Name
Glostrup Hospital - Department of Neurology
City
Glostrup
ZIP/Postal Code
2600
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Helle Iversen, MD
Phone
+45 38 63 38 63
Email
helle.klingenberg.iversen@regionh.dk
Facility Name
Herlev-Gentofte Hospital - Department of Medicine
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kasper Iversen, MD
Email
kasper.karmark.iversen@regionh.dk
Facility Name
Nordsjællands Hospital - Hillerød
City
Hillerød
ZIP/Postal Code
3400
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Louise Schierbeck, MD
Phone
+45 48 29 48 29
Email
louise.schierbeck.01@regionh.dk
Facility Name
Hjørring Hospital
City
Hjørring
ZIP/Postal Code
9800
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Albert M Johnsen, MD
Email
albert.marni.joensen@rn.dk
First Name & Middle Initial & Last Name & Degree
Albert M Johnsen, MD
Facility Name
Holbæk Hospital
City
Holbæk
ZIP/Postal Code
4300
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne MB Soja, MD
Email
amsj@regionsjaelland.dk
First Name & Middle Initial & Last Name & Degree
Peter Hallas, MD
First Name & Middle Initial & Last Name & Degree
Anne MB Soja, MD
Facility Name
Hvidovre Hospital
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jens Hove, MD
Phone
38 62 38 62
Email
Jens.Dahlgaard.Hove@regionh.dk
First Name & Middle Initial & Last Name & Degree
Christian Rasmussen, MD
Facility Name
Næstved Hospital
City
Næstved
ZIP/Postal Code
4700
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frida Yrjans, MD
Email
fyr@regionsjaelland.dk
Facility Name
Odense University Hospital - Department of Cardiology
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gro Egholm, MD
Email
gro.egholm@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Gro Egholm, MD
Facility Name
Odense University Hospital - Department of Emergency Medicine
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mikkel Brabrand, MD
Email
Mikkel.Brabrand@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Mikkel Brabrand, MD
Facility Name
Odense University Hospital - Department of Geriatrics
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Azra Osmanagic, MD
Email
Azra.Osmanagic@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Azra Osmanagic, MD
First Name & Middle Initial & Last Name & Degree
Jesper Ryg, MD
Facility Name
Zealand University Hospital - Department of Neurology
City
Roskilde
ZIP/Postal Code
4000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Troels Wienecke, MD
Email
trw@regionsjaelland.dk
Facility Name
Zealand University Hospital Roskilde - Department of Cardiology
City
Roskilde
ZIP/Postal Code
4000
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Bang, MD
Email
cbng@regionsjaelland.dk
Facility Name
Bornhoms Hospital
City
Rønne
ZIP/Postal Code
3700
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kjeld Kristensen, MD
Phone
+45 38 67 00 00
Email
kjeld.skoedebjerg.kristensen@regionh.dk
Facility Name
Slagelse Hospital
City
Slagelse
ZIP/Postal Code
4200
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gitte G Fornitz, MD
Email
gfor@regionsjaelland.dk
Facility Name
Odense University Hospital Svendborg
City
Svendborg
ZIP/Postal Code
5700
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jess Lambrechtsen, MD
Email
Jess.Lambrechtsen@rsyd.dk
Facility Name
Vejle Hospital
City
Vejle
ZIP/Postal Code
7100
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lone K Andersen, MD
Email
Lone.Kaerslund.Andersen@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Lone K Andersen, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Links:
URL
http://dannoac.dk
Description
DANNOAC study webpage

Learn more about this trial

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

We'll reach out to this number within 24 hrs